Drugs / ATEXAKIN ALFA
ATEXAKIN ALFA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05435742 | Oct 2022 → Mar 2024 | chemotherapy-induced neuropathy | Sonnet BioTherapeutics | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATEXAKIN ALFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108992 ↗ |
| Known as | Atexakina alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108992 ↗ |
| Known as | Atexakine alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108992 ↗ |
| Known as | Recombinant interleukin 6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108992 ↗ |
| Known as | SON-080 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05435742 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2108992 ↗ |
| Route | Subcutaneous | “Repeated Subcutaneous Administration of SON-080” NCT05435742 ↗ |